Kondo, Masahiro
Suzuki, Tsuyoshi
Kawano, Yuko
Kojima, Shinji
Miyashiro, Masahiko
Matsumoto, Atsuhiro
Kania, Gabriela
Błyszczuk, Przemysław
Ross, Rebecca L.
Mulipa, Panji
Del Galdo, Francesco
Zhang, Yun
Distler, Jörg H. W.
Article History
Received: 1 April 2022
Accepted: 17 August 2022
First Online: 1 September 2022
Declarations
:
: BLM-induced SSc murine model—prophylactic evaluation: the study was conducted in accordance with the Guidelines for Animal Experimentation of Mitsubishi Tanabe Pharma Corporation (approval number: BJ14-0699).BLM-induced SSc murine model—therapeutic evaluation: the study was conducted in accordance with the European Community Council Directive for Care and Use of Laboratory Animals and the Swiss law (approval number: ZH002/17).Skin biopsy samples and fibroblast isolation (fibroblast assay): all patients with dcSSc and healthy donors provided written informed consent through the stratification for risk of progression in scleroderma (STRIKE SSC), which had been approved by the North–East Research Ethics committee (approval number 15/NE/0211).Skin biopsy samples (immunohistochemical analysis of MC1R): the study was approved by the ethical review board of the Medical Faculty of the University of Erlangen–Nuremberg (number 3766). All patients with SSc and healthy donors provided written informed consent as approved by the institutional ethics committee.
: Prof. F. Del Galdo received fees and research support from Abbvie, AstraZeneca, Boehringer-Ingelheim, Capella, Chemomab, Kymab, Janssen, and Mitsubishi-Tanabe.Prof. J.H.W. Distler received consulting fees, lecture fees, and/or honoraria from Actelion, Active Biotech, Anamar, ARXX, aTyr, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, GSK, Inventiva, JB Therapeutics, Medac, Pfizer, Sanofi-Aventis, RedX, RuiYi, and UCB. J. H. W. Distler is the stock owner of 4D Science and Scientific head of FibroCure.M. Kondo, T. Suzuki, Y. Kawano, and S. Kojima are employees of Mitsubishi Tanabe Pharma Corporation.